The FDA approves Wegovy HD (semaglutide 7.2 mg) for chronic weight management in adults with obesity or overweight and weight-related conditions.

Aro Reports Positive Phase 1b Topline Results for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD) ...

New randomized controlled trial to evaluate dose-dependent effects of oral THC on anxiety and stress using Avicanna’s ...

Phoenix-based moving company earns national recognition from Forbes for quality, reliability, and customer experience ...

Ophthalmology is the highest volume outpatient specialty within the NHS and the medicines used for medical retinal vascular conditions account for some of the highest cost and volume treatments used ...

The weight-loss drug market just got more crowded — and a lot less painful. The FDA on Monday approved a daily pill version of Novo Nordisk’s Wegovy, making it the first oral GLP-1 obesity treatment ...

The US Food and Drug Administration on Monday approved a daily pill version of Novo Nordisk's weight-loss drug Wegovy, introducing a new option for how patients can take medicines in a class of drugs ...

Approximately half the worldwide population is at risk for dengue. No antiviral prophylaxis or treatment options are available. In a phase 2a, double-blind, randomized trial, we assigned healthy ...

Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches Fig 1. Study schema of the GENTLE-Z trial. Patients with previously untreated, CLDN18.2-positive, ...

The article by Assenat et al entitled “Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized ...

Kirstyn Hill has worked as a clinical pediatric and women’s health pharmacist since 2020. She was driven to work with a patient population that is not often able to easily speak up for themselves and ...

New data from Biogen shows improved motor function in SMA patients using a higher dose of nusinersen, highlighting early treatment benefits. Biogen announced new data from the DEVOTE Part C and ...